Apr, 2006

U.S.A.
News / Therapeutic Area News
Astellas Launches VAPRISOL® for the Treatment of Euvolemic Hyponatremia in Hospitalized Patients
Astellas Pharma US, Inc. today announced the launch and commercial availability of VAPRISOL® (conivaptan hydrochloride injection), an arginine vasopressin (AVP) receptor antagonist for the...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan
MELVILLE, N.Y.--(BUSINESS WIRE)--April 17, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that a New Drug Application has been submitted in Japan covering the use of its flagship...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Receives FDA Approval of Prograf® (Tacrolimus) for use in Heart Transplans Recipients
DEERFIELD, IL, APRIL 1, 2006 – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf as an immunosuppressant to prevent organ rejection in...
Read More
U.S.A.
News / Therapeutic Area News
New Drug Application Submitted for RSD1235
Vancouver, Canada and Deerfield, Illinois, USA, March 31, 2006 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced...
Read More

Feb, 2006

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Fourth Quarter Net Sales for Tarceva(R)'s International Launch; Tarceva World-wide Sales Reached $309 Million in 2005
MELVILLE, N.Y., Feb 01, 2006 -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter international sales for its flagship product, Tarceva® (erlotinib). Net international sales...
Read More